Latest Apollo Projects
Bispecific mAb targeting and activating through CEA / 4-1BB for immuno-oncology
By Richard Butt
a collaboration with Prof Kerry Chester, University College London, and Cyclogenix
Prof Kerry Chester, University College London Cancer Institute and Cyclogenix have fused an anti-CEA antibody that recognises tumour cells with a novel cyclotide that binds the T-cell activating receptor 4-1BB as a potential immune-oncology therapeutic agent. Based on this research, Apollo, University College London and Cyclogenix teams are now collaborating to identify and optimise a bispecific agent for testing in preclinical in vitro and in vivo studies.
< PREV ITEM | > NEXT ITEM Targeting viral packaging, a highly conserved process in HIV lifecycle as a novel anti-viral